Skip to main content
BuzasGyorgy_Helicobacter_pylori

 

Irodalom:
1. Linz, B., Ballous, F., Moodley, Y. és mtsai: An African origin for the intimate association between
humans and Helicobacter pylori. Nature 2007; 445:915-918.
2. Lehours, P., Yilmaz, O.: Epidemiology of Helicobacter pylori infection. Helicobacter 2007; 12: Supplement
1, 1-3.
3. Myrén, O.: Helicobacter pylori infection, peptic ulcer disease and gastric cancer, in: GI Epidemiology,
szerk. N.J.Talley., G.Richard Locke III, Y.A.Saito, Blackwell Publishing, 2007; 124-142.
4. Azevedo, N.F., Guimarães, N., Figueiredo, C., Vieira, M.J.: A new model for the transmission of
Helicobacter pylori: role of environmental reservoirs as gene pools to increase strain diversity. Critical
Reviews in Microbiology, 2007; 33:157-169.
5. Thodleifsson, B., Asbjörndottir, H., Sigurjonsdottir, R.B. és mtsai: Seroprevalence of Helicobacter pylori
and cagA antibodies in Iceland, Estonia and Sweden. Scand.J.Infect. Dis., 2007; 39:683-689.
6. Takáts A., Egri G., Csíki Z. és mtsai: Significant decrease of the Helicobacter pylori infection in Budapest,
Gut, 2007;56:Supplement III, A90.
7. Lakatos G., Herszényi L., Juhász M. és mtsai: The incidence of gastroduodenal ulcers, gastrooesophageal
reflux disease and Helicobacter pylori infection between 1995 and 2005. MGT 49. Nagygyûlés, 2007;
558 Gastro Update 2008
109/A97. és Z.Gastroenterol., 2007;44:433/49.
8. Sonnenberg, A.: Time trends of ulcer mortality in Europe. Gastroenterology, 2007,132:2320-2327.
9. Correa, P., Houghton, J.: Carcinogenesis of Helicobacter pylori. Gastroenterology, 007;133:659-672.
10. Hagymási K., Molnár B., Sípos F., Galamb O., Tulassay Zs.:A colorectalis rák kialakulásának õssejtelmélete
és összefüggése a molekuláris biológiai adatokkal. Orv. Hetil., 2007;148:779-785.
11. Wu, XZ, Yu, XH.: Bone marrow cells: the source of hepatocellular carcinoma? Med. Hypotheses, 2007;
69:36-42.
12. García-González, M.A., Lanas, A., Quintero, E. és mtsai: Gastric cancer susceptibility is not linked to
pro-and anti-inflammatory cytokine gene polymoerphisms in whites: a nationwide multicenter study in
Spain. Am.J.Gastroenterol, 2007;102: 1878-1892.
13. Nakamura, S., Ye, H., Bacon, C.M. és mtsai: Clinical impact of genetic alterations in gastric MALT
lymphoma: a comprehensive analysis using interphase fluorescense in situ hibridization. Gut, 2007;
56:1358-1363.
14. Malfertheiner, P., Mégraud, F., O’Morain, C. és mtsai: Current concepts in the management of Helicobacter
pylori infection: the Maastricht III Consensus Report. Gut, 2007;56:772-781.
15. Chey, D.W., Wong, B.C.: Practice Parameters Committee of the American College of Gastroenterology:
Americamn College of Gastroenterology guideline on the management of Helicobacter pylori infection.
Am.J.Gastroenterol., 2007;102:1808-1825.
16. Caselli, M., Zullo, A., Maconi, G. és mtsai: “Cervia II Working Group Report 2006”: guideline on diagnosis
and treatment of Helicobacter pylori infection in Italy. Dig. Liver Dis., 2007;39:782-792.
17. Malfertheiner, P., Vieth, M.: Gastritis und Gastropathie, in: Gastroenterologie, szerk. J. F. Riemann,
W. Fischbach, P. R. Golde, J. Mössner, Thieme Verlag, Stuttgart, 2007, I.kötet, 514-524.
18. Mégraud, F., Lehours, P.: Helicobacter pylori detection and susceptibility testing. Clin Micribiol. Rev.,
2007;20:280-322.
19. Sipponen, P., Graham, D.Y.: Importance of atrophic gastritis in diagnostics and prevention of gastric
cancer: application of plasma biomarkers. Scand. J. Gastroenterol., 2007; 42: 2-10.
20. Buzás Gy.M., Széles I.: Interpretation of the 13C-urea breath test in the choice of second- and third-line
eradication of Helicobacter pylori infection. J.Gastroenterol., 2008; 43:2.
21. Zullo, A., Perna, F., Ricci, C. és mtsai: 13C-urea breath test values and Helicobacter pylori eradication,
Dig.Dis. Sci., 2007;52:767-773.
22. Wang, S., Yuan, Y., Hunt, R.H.: The association between Helicobacter pylori infection and early gastric
cancer: a meta-analysis. Am.J.Gastroenterol., 2007;102: 1789-1798.
23. Rokkas, T., Pistiolas, D., Sechopoulos, P. és mtsai: Relationship between Helicobacter pylori infection
and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol., 2007.11.6. (epub ahead of
print).
24. Shimada, T., Yamagata, M., Hiraishi, H.: Role of Helicobacter pylori eradication in the prevention of
peptic ulcer in NSAID-ulcers. Nippon Rinsho, 2007; 65: 1824-1829.
25. Jin, X., Li, Y.M.: Systematic review and meta-analysis from Chinese literature: the association between
Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12:541-546.
26. Moayyedi, P.: The health economics of Helicobacter pylori infection, Best Pract. Res. Clin. Gastroenterol.,
2007; 21: 347-361.
27. Rodgers. C., van Zanten,S.V.: A meta-analysis of the success rate of Helicobacter pylori therapy in
Egyéb 559
Canada. Can. J. Gastroenterol., 2007; 21: 295-300.
28. Fuccio, L., Minardi, M.E., Zagari, R.M. és mtsai: Meta-analysis: duration of first-lined proton-pump
inhibitor-based triple therapy for Helicobacter pylori eradication. Ann. Intern.Med., 2007; 147: 553-562.
29. Zullo, A., De Francesco, V., Hassan, C. és mtsai: The sequential therapy regimens for Helicobacter
pylori eradication: a pooled-data analysis. Gut, 2007; 56: 1353-1357.
30. Delgado, J.S., Margiotta, M., Gisbert, J.P. és mtsai: Effectiveness of a 10-day sequential treatment for
Helicobacter pylori eradication in clinical practice. Gastroenterology, 2007; 132: Supplement 2, A112.
31. Buzás Gy. M., Józan J.: Systematic review and meta-analysis: nitrofuran-based regimens for the eradication
of Helicobacter pylori infection. J. Gastroenterol. Hepatol., 2007; 22: 1571-1581.
32. Khurana, R., Fischbach, L., Chiba, N. és mtsai: Meta-analysis: Helicobacter pylori
eradication treatment efficacy in children. Aliment. Pharmacol. Ther., 2007; 25: 523-536.
33. Dezsõfi A., Arató A.: Gasztroduodenális megbetegedések gyermekkorban. Eur. J. Gastroenterol. Hepatol.
(magyar kiadás), 2007;11:161-165.
34. Vakil, N., Mégraud, F.: Eradication therapy for Helicobacter pylori. Gastroenterology, 2007; 133: 985-1001.
35. Fischbach, L., Evans, E.L.: Meta-analysis: the effect of antibiotic resistance status on the efficacy of
triple and quadruple first-line therapies for Helicobacter pylori. Aliment. Pharmacol. Ther., 2007; 26: 343-357.
36. Mégraud, F.: Helicobacter pylori and antibiotic resistance. Gut, 2007; 56: 1502.
37. Buzás Gy.M., Lotz G., Kiss A.: A clarithromycin-rezisztencia magyarországi
epidemiológiája Helicobacter pylori fertõzésben. Orv. Hetil., 2007; 148: 1461-1467.
38. De Francesco, V., Margiotta, M., Zullo, A. és mtsai: Prevalence of primary clarithromycin resistance in
Helicobacter pylori strains over a 15 year period in Italy. J. Antimicrob. Chemother., 2007; 59: 783-785.
39. Perna, F., Zullo, A., Ricci, C. és mtsai: Levofloxacin-based triple therapy for Helicobacter pylori
re-treatment: role of bacterial resistance. Dig. Liver Dis., 2007; 39: 1001-1005.
40. Furuta, H., Shirai, N ., Kodairas, M. és mtsai: Pharmacogenomics-based tailored versus standard therapeutic
regimen for eradication of H. pylori. Clin.Pharmacol.Ther., 2007; 81: 521-528.
41. Spengler G.:Attempts to reduce drug resistance of bacteria and cancer cells. Hung. Med. J., 2007; 1: 109-125.
42. Gisbert, J.P., Bermejo G., Castro-Fernandez, M. és mtsai: Second-line rescue therapy with levofloxacin
after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am.J.Gastroenterol.,
2007, 102: 1182-1187.
43. González Carro, P., Pérez Roldán, F., De Pedro Esteban, F. és mtsai: Efficacy of rifabutin-based triple
therapy in Helicobacter pylori infected patients after two standard treaments. J. Gastroenterol. Hepatol.,
2007; 22: 60-63.
44. Supuran, C.T.: Novel targets against Helicobacter pylori: a bioinformatic approach.Future Microbiol.,
2007; 2: 111-114.
45. Scott, D.M., Marcus, E.A., Wen, Y., Oh, J., Sachs, G.: Gene expression in vivo shows that Helicobacter
pylori colonizes acidic niche on the gastric surface. Proc. Natl. Acad.Sci., 2007; 104: 7235-7240.
46. Nishimori, S.,. Minakuchi, T., Koshaki, T. és mtsai: Carbonic anhydrase inhibitors: carbonic anhydrase
from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorganic and
Medicinal Chemistry Letters, 2007; 17: 3585-3594.
47. Hoffman, P.S., Sission, G., Cropxen, M.A. és mtsai: Antiparasitic drug nitazoxanide inhibits the pyruvate
oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter
jejuni. Antimicrob. Agents Chemother., 2007; 51: 868-876.
560 Gastro Update 2008
48 Bohr, U.M.R., Annibale, B., Francheschi, F. és mtsai: Extragastric manifestations of Helicobacter pylori
infections -other Helicobacters. Helicobacter 2007; 12: Suppl.1., 41-53.
49. Franchini, M., Cruciani, M., Mengoli, C., Pizzolo, G., Veneri,D.: Effect of Helicobacter pylori eradication
on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis.
J. Antimicrob.Chemother., 2007; 60:237-246.
50. Kanbay, M., Kanay, A., Boyacioglu, S.: Helicobacter pylori infection as a possible risk factor for respiratory
system disease: a review of the literature. Respiratory Med., 2007; 101: 203-209.
51. Chen, D.F., Hu, L., Wen Liu, W. és mtsai: H. pylori are associated with chronic cholecystitis. World J.
Gastroenterol., 2007; 21: 1119-1122.
52. Goldberg, D., Szilágyi, A., Graves, L.: Hyperemesis gravidarum, and Helicobacter pylori infection: a
systematic review. Obstet. Gynecol., 2007; 110: 695-703.
53. Visy B., Füst Gy., Bygum, A. és mtsai: Helicobacter pylori infection as triggering factor of attacks in
patients with hereditary angiooedema. Helicobacter 2007; 12: 251-258.
54. Shiotani, A., Miyanishi, T., Kamada, T., Haruma, K.: Helicobacter pylori infection and allergic disease:
epidemiological study in Japanese university students. J. Gastroenterol. Hepatol., 2007;22:787-793.
55. Chen, Y., Blaser, M.J.: Inverse associations of Helicobacter pylori with asthma and allergy, Arch. Intern.
Med., 2007; 167: 821-827.
56. Galamb O., Gyõrffy S., Sípos F. és mtsai: Helicobacter pylori and antrum erosion specific gene expression
patterns: the discriminative role of CXCL 13 and VCAM13 and VCAM1 transcripts. Helicobacter,
2007,12: in press és XVI.Nemzetközi Semmelweis Szimpózium és VI. Magyar Sejtanalitika Konferencia.
Molekluláéris gasztroenterológia, sejtanalitika, “array” technológiák, Budapest, 2007, 38-40.
57. Galamb O., Sípos F., Molnár B. és mtsai: Evaluation of malignant and benign gastric biopsy specimens
by mRNA expression profile and multivariate statistical methods. Cytometry B Clin.Cytom., 2007;
72: 299-309.
58. Dömötör, A., Kereskay, L., Szekeres, G. és mtsai: Participation of capsaicin-sensitive afferent nerves in
the gastric mucosa of patients with Helicobnacter pylori-positive or -negative chronic gastritis.
Dig. Dis. Sci., 2007; 52:411-417.
59. Horváth M., Garamszegi, M ., Bogner B ., Beró T.: Egy ritka endoszkópos kórkép: gyomor
micropneumatosis. Orrv.Hetil., 2007; 148: 799-802.

Leave a Reply